PET-guided surgery for high-grade glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, non-randomized observational comparison of 18F-DOPA PET-guided resection versus conventional MRI-guided resection in patients with high-grade glioma. Surgeons integrate PET metabolic maps with standard MRI to define targets for supramaximal resection beyond contrast-enhancing regions and FLAIR abnormalities. Outcomes include progression-free survival and overall survival, with preoperative imaging, surgical extent-of-resection metrics, and follow-up clinical and radiographic assessments. The study enrolls adult surgical candidates at participating centers in Genoa and Turin, Italy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age ≥18 years
* high-grade glioma (WHO grade III/IV) diagnosed on MRI
* provide written informed consent

Exclusion Criteria:

* tumors located in the cerebellum, brainstem, or midline.
* Patients with medical conditions precluding MRI
* inability to provide written informed consent
* secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma
* other primary malignancy within the past five years

Where it's running

• AOU Città della Salute e della Scienza
  Torino, Turin, Italy Recruiting
• IRCCS Azienda Ospedaliera Metropolitana
  Genova, Italy Recruiting

Study contacts

• Study coordinator: Andrea Bianconi, MD
• Email: andrea.bianconi@unige.it
• Phone: +393475805577

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Midline glioma MRI AI model: preoperative molecular subtyping and prognosis

  This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07608003

• Language Network Prehab with fMRI Neurofeedback before Glioma Surgery

  This study tests whether brief fMRI neurofeedback before glioma surgery can help shift language brain activity away from tumor-affected areas.

  Recruiting Yale University · New Haven, Connecticut · NCT07488780

• mRNA vaccine targeting common glioma mutations for recurrent or progressive high-grade glioma

  This trial will test an mRNA vaccine that targets common glioma mutations to see if it is safe and helps the immune system fight recurrent or progressive high-grade glioma.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07306299

• Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP

  This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.

  Recruiting at 15 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 14 other locations · NCT06810544

• Evaluating a new PET imaging agent for prostate cancer diagnosis

  This study is testing a new imaging agent for prostate cancer to see if it can help doctors find and monitor the disease more accurately than current methods.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06696326

• Injection of natural killer cells for treating gliomas

  This study is testing whether a new treatment using natural killer cells can help young patients with high-grade gliomas, like glioblastoma, fight their cancer better.

  Recruiting Phase 2 Kian Immune Cell Company · Tehran · NCT06687681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.